Heather D. Brooks - Concepedia

Author

Heather D. Brooks

The US Oncology Network

Also Known As

H. Brooks, H. D. Brooks, H.D. Brooks, Heather Brooks, Heather D. Brooks, Heather Dawn Brooks

Publications

273

Citations

H-Index

Concepts

All Affiliations

The US Oncology Network Rocky Mountain Cancer Centers Prisma Health Willamette Valley Cancer Institute and Research Center The University of Texas MD Anderson Cancer Center

About

Heather D. Brooks is an author at The US Oncology Network specializing in medicine, cancer research, and cancer therapeutics.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	3	3	52
2	Health Sciences	2	2	33
3	Pathology	2	2	33
4	Immunology	1	1	21
5	Pharmacology	1	1	12

Heather D. Brooks

Publications

246

Citations

H-Index

Page 1

	Year	Citations
Phase 2 study of dasatinib in the treatment of head and neck squamous cell carcinoma Heather D. Brooks, Bonnie S. Glisson, B. Nebiyou Bekele, Cancer	2010	106
Ublituximab ( <scp>TG</scp> ‐1101), a novel glycoengineered anti‐ <scp>CD</scp> 20 antibody, in combination with ibrutinib is safe and highly active in patients with relapsed and/or refractory chronic lymphocytic leukaemia: results of a phase 2 trial Jeff P. Sharman, Charles M. Farber, Daruka Mahadevan, British Journal of Haematology	2016	62
Phase IIIb randomized study of lenalidomide plus rituximab (R<sup>2</sup>) followed by maintenance in relapsed/refractory NHL: Analysis of patients with double-refractory or early relapsed follicular lymphoma (FL). David Andorsky, Abdulraheem Yacoub, Jason M. Melear, Journal of Clinical Oncology Cancer ManagementImmunologyInitial DiagnosisPathologyPharmacotherapy	2017	21
Isolated Polyarticular Septic Arthritis: An Atypical Presentation of Meningococcal Infection Michael A. McCulloch, Heather D. Brooks, Kambiz Kalantarinia The American Journal of the Medical Sciences RheumatologyPolyarticular Septic ArthritisClinical InfectionBacterial MeningitisMedicine	2008	19
Ublituximab (TG-1101), a Novel Glycoengineered Anti-CD20 Monoclonal Antibody, in Combination with Ibrutinib Is Highly Active in Patients with Relapsed and/or Refractory CLL and MCL; Results of a Phase II Trial Jeff P. Sharman, Charles M. Farber, Daruka Mahadevan, Blood	2014	15
Phase II study of dasatinib in the treatment of head and neck squamous cell carcinoma (HNSCC) Heather D. Brooks, Bonnie S. Glisson, Charles Lu, Journal of Clinical Oncology Dasatinib 100Cancer ManagementPathologyPhase Ii StudyTreatment Resistance	2009	12
MAGNIFY: Phase IIIb Randomized Study of Lenalidomide Plus Rituximab (R2) Followed By Lenalidomide Vs. Rituximab Maintenance in Subjects with Relapsed/Refractory Follicular, Marginal Zone, or Mantle Cell Lymphoma David Andorsky, Abdulraheem Yacoub, Jacob D. Bitran, Blood	2016	11

Page 1